GAMMA Investing LLC Buys 967 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

GAMMA Investing LLC lifted its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 106.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,874 shares of the biotechnology company’s stock after acquiring an additional 967 shares during the quarter. GAMMA Investing LLC’s holdings in ADMA Biologics were worth $32,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ADMA. USA Financial Formulas increased its position in shares of ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after buying an additional 539 shares during the period. Vontobel Holding Ltd. grew its stake in shares of ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 888 shares during the period. Hollencrest Capital Management bought a new stake in ADMA Biologics in the 3rd quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. raised its stake in ADMA Biologics by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after buying an additional 1,509 shares during the period. Finally, Larson Financial Group LLC bought a new position in shares of ADMA Biologics in the 3rd quarter worth $31,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $16.32 on Wednesday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52 week low of $4.82 and a 52 week high of $23.64. The company has a market cap of $3.86 billion, a PE ratio of 58.29 and a beta of 0.76. The business has a 50 day moving average of $19.29 and a 200 day moving average of $17.23.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the previous year, the firm posted $0.01 EPS. As a group, equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Raymond James upped their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.